Pharmaceutical Technology Europe, Jul 1, 2011 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Jul 1, 2011
By Stephanie Sutton
The coming years will show a slowing growth rate in the global spending of medicines, particularly when it comes to branded products.
Supply Chain
Degradation And What It Means To The Supply Chain
By Duane Sword
Product degradation is often overlooked compared with other supply chain issues, but if left unchecked can lead to the market entry of substandard medicines, whether through ignorance or gross negligence.
Industry Insider
Swiss Pharma Strength
By Nathan Jessop
Switzerland is an important power in Europe's pharmaceutical industry.
Achieving Lean Processing With Single-Use Systems
By Vikas Gupta
Single-use filtration and fill–finish technologies can be used as part of a lean manufacturing strategy to boost production, and reduce manufacturing waste and costs.
Special Feature
The Decontamination Challenge
By James Drinkwater
The increase in aseptic processing driven by the growing number of biologically-derived products has led to an increase in freeze-drying applications in this area at both research and production scales.
Controlling Nucleation
By Mark Shon
Ideally, all product formulations should experience the same conditions when it comes to lyophilisation, but in practice, however, nucleation can occur.
Innovation And R&D In Freeze-Drying
By Isobel Cook
Lyophilisation or freeze-drying is widely used in the pharmaceutical industry for a variety of reasons.
Overcoming Common Lyophilization Scale-Up Issues
By Antonello Barresi
The same recipe obtained in laboratory-scale equipment cannot, without modifications, generally be used to freeze-dry the product in a pilot-scale or industrial-scale freeze-dryer.
Editor's Comment
Swiss, Please!
By Rich Whitworth
One of the perks of my job is that I can travel to previously unvisited cities. This month, I was lucky enough to be in Switzerland.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here